The firm recently brought on SVPs in its Washington and Boston offices.
Dermira likely to shelve experimental acne drug; Biotech companies apply to use Crispr gene-editing tool; Another setback for Santhera's Raxone.
The pharmaceutical company is undergoing a global restructuring as it relaunches its brand in the U.S. and Canada.
The results will appear in MM&M's Agency A-to-Z directory, which will appear in the magazine's July issue.
Uber rolls out rides to doctor appointments; Trump calls for federal suit against opioid makers; Biogen, AbbVie pull marketing for Zinbryta.
The firm has named Oliver Caporn and Debra Polkes to new roles.
The Cannes Lions Health jury leaders also explained changes to the awards at an event in New York this week.
WPP segment including health and wellness outperforms rest of holding company in Q4; Novartis partners with Pear on app development; Study: 3 million-plus Americans could join association health plans in four years.
From Muse: Michelle Obama on making consumers comfortable with med tech (and thinking before she tweets)
The former first lady spoke at Klick Health's Muse event, which also featured panels on gene therapy, health technology, and immunotherapy.
FDA declines to review potential Celgene MS blockbuster; AstraZeneca to spin off autoimmune drug unit; Justice Department to back prescription opioid lawsuit.
Heal CEO Nick Desai aims to improve the patient experience by providing an on-demand service that cuts time and costs while increasing human interaction.
Boston Children's Hospital and Klick Health are unveiling a VR tool to help pediatric patients visualize their disease and symptoms. It could augment the paper-based standard of care.
Apple plans California healthcare clinics for staff; Aldeyra strikes inflammatory disease drug pact with J&J; 20 states sue feds to end Obamacare.
The platform is looking to focus its communications strategy on the U.S. market.
FDA approves KemPharm's Apadaz; Buffett says healthcare alliance will do more than cut out middlemen; Customers unhappy with price of Teva's Syprine generic.
Virta Health CEO Sami Inkinen on changing patient behavior: 'We're cutting down trees in the wrong forest'
Seven questions for the Virta Health chief executive and cofounder of Trulia.
Pharma buys back shares with tax savings; Facebook algorithm change means opportunity for patient influencers; Trump claims Azar has already lowered drug prices.
A WEGO Health white paper examined how the change could affect patient influencers.
Novo Nordisk diabetes pill delivers in late-stage trial; Gilead partners with Sangamo on engineered cell therapies; Study finds antidepressants work, though with varying results.
Dohmen will continue to operate under its brand and retain its leadership team.
AbbVie reports successful elagolix trial; White House touts short-term insurance plans; Mayo Clinic chief to retire.
Talukdar will lead the firm's advisory practice, VantageRx.
Gilead wins reversal of $2.5 billion payment order; Aimmune Therapeutics' peanut allergy therapy shows promise; AstraZeneca wins FDA approval on key cancer drug.
Roche to acquire Flatiron Health for $1.9B; FDA considers allowing pre-symptom Alzheimer's drug tests; Marijuana producer branches into pharma.
The agency began working with the national reproductive center this month.
CMS forecasts prescription drug spending to hit $5.7T by 2026; Ipsen predicts cancer drug shopping spree; Omnicom numbers miss estimates on revenue.
The two organizations will partner on content including personal stories and expert advice.
In 2017, Interpublic reported a net income of $579 million, down 4.8% from the previous year.
IPG 2017 net income drops; Bristol-Myers Squibb inks $1.85 billion deal with Nektar on cancer drug; Merck halts final-stage Alzheimer's drug.
Daniel Carucci is joining the Interpublic Group firm full-time after serving as a consultant and in roles with the U.N. Foundation and the U.S. Navy.
The company is also looking to better combine its web and social media presence.
Zimprich joins from Honeywell, where he led global business communications.
Amazon moves into medical supply market; Big Pharma gets a tax cut; Former Celgene CEO plans Senate run.
The pharma company manufactures the well-known opioid OxyContin.
Healthcare providers may understand its importance, but across the board not many are ready to meet the requirements of the program QPP, according to a study.
As the evidence mounts that high-deductibles don't cause patients to shop or save for healthcare, payers are taking note.
White House limits guidance documents; Top executives exit Axovant; Carroll nominated as drug czar.
Study: Two prostate cancer drugs delay metastasis by two years; Budget deal funds CHIP for four years; Azar outlines Trump's drug pricing plans.
PhRMA wants to clear the air about drug pricing with the consumer-focused extension of the Let's Talk About Cost campaign.
Critics said the initial spots unnecessarily blamed IBD sufferers.
FDA approval of Gilead HIV drug prompts ViiV patent suit; Poll shows split in voter reaction to Trump opioid plan; Outcome Health partners with CDC.
Study casts doubt on employee wellness programs; FDA identifies kratom as an opioid; House passes bill to modify ACA restaurant menu rules.
LiquidHub formed a health- and life-sciences-focused offering last June after acquiring Eveo.
Burcin, who joins from Klick Health, is the former Global CEO of Havas Health.
The agency M&A market is changing as the big ad groups have been "distracted" by internal restructuring and new acquirers are emerging.
Allergan Q4 earnings beat estimates; Mars publishes research policies; Conway takes control of White House opioid agenda.
Snow Companies, which emphasizes patient storytelling, was founded by Brenda Snow in 2001.
McCann Worldwide has sent a memo to staff to encourage them to speak up if they face a 'behaviour or concern' in the workplace.
Opdivo hits key goal in late-stage trial; Philippines government sues Sanofi over anti-dengue vaccine; hospitals reach capacity amid record flu season.
This year, the Super Bowl and World Cancer Day fall on the same date.
AstraZeneca strikes deals with Alibaba, Tencent; NY AG sues opioid maker; Justice Department wants more info on CVS-Aetna deal.
Amazon's ability to attract other employers makes its healthcare coalition very formidable, experts say
Details are vague, but the e-commerce giant indicated it's serious about getting into healthcare.
The network also appointed her predecessor, Nick Colucci, as COO of Publicis Communications North America, effective immediately.
Childs has worked at the network news division for more than a decade.
Vertex moves two cystic fibrosis drugs into Phase III trials; American Heart Association says breast cancer survivors have higher risk of cardiovascular disease; Blood test to predict Alzheimer's shows promise.
Glaze worked in Edelman's market access practice for more than seven years.
The nonprofit worked with creative agency E/LA on the push.
CDC chief resigns; Amazon healthcare entry raises data concerns; Trump promises to make lower drug prices 'a priority'
Burson-Marsteller has appointed MSLGroup's EMEA head of healthcare to lead its own health practice in the UK, PRWeek has learned.
Jardiance treats patients with type 2 diabetes and heart disease, lowering blood sugar and reducing the risk of death from heart disease.
Amazon, Berkshire Hathaway, and JPMorgan team up to form a healthcare company; Takeda's Zika vaccine receives FDA fast-track status
Publicis Groupe has announced it has selected Microsoft has the technology partner to deliver its artificial intelligence platform Marcel.
Alan Maine has joined Edelman as a senior director in its London health team.
Outcome Health settles fraud allegations, reassigns leaders; Approval of generics surges during first year of Trump administration; Sanofi acquires coveted biotech firm.
WPP was brought on to help with consumer education about the food industry.
For some pharma brands, the price tag is just too high. For others, the platform isn't serious enough.
Pharma groups upped lobbying spend in 2017; Novartis, Bayer heads dine with Trump at Davos; Illumina wins jury verdict against Roche subsidiary
Fidelino served on the Health & Wellness jury in 2015 and the Pharma jury last year. Levy has been a member of both Health category juries and was a speaker at the first Health Lions in 2014.
Somatix is a digital health platform that tracks movements through smartwatches.
Senate confirms Azar as HHS head; Spark licenses Luxturna to Novartis outside the U.S.; Glaxo and J&J top index of superbug combatants
Warc anticipates global adspend growth this year to ring in at a healthy 4.7%, or $572bn (£410bn).
WPP has become embroiled in a row over sexism and misogyny following an exposé into the lewd behaviour of a men-only event sponsored by the advertising giant in London.
Novartis sees single-digit growth with new CEO; J&J takes $13.6b charge in the wake of the new tax law; New York City invests in biotech
FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW
Some microinfluencers see the latest YouTube guidelines as a "slap in the face."
Nick Law, the global chief creative officer of R/GA, is leaving the company after 17 years to take on the newly created role of chief creative officer across Publicis Groupe and president of Publicis Communications.
Sanofi to buy Bioverativ for $11.6 billion; Celgene to acquire Juno for $9 billion; Teva to lay off more than 200 in Philadelphia
She is overseeing three of the network's agencies in the newly created role.
Advertisers have until July to get their mobile pages up to speed.
Biogen, UCB reportedly showing interest in Acorda acquisition; Kite Pharma and Pfizer to develop combo lymphoma therapy; hospitals to form generics nonprofit
Senate committee votes in favor of Azar as new HHS head; FDA and DoD launch breakthrough designation program; Walmart offers free opioid disposal solution
The CEO of the independent healthcare agency discusses growing a business in digital in the early 2000s and the perks of remaining independent.
In an effort to assure advertisers and agencies on brand safety, Google has announced two new requirements for video creators that intend to join the YouTube Partner Program.
Celgene reportedly in talks to buy Juno; Novartis' Kymriah receives fast-track reviews in U.S. and Europe; BI's Gilotrif gets expanded approval in lung cancer
Although if approved, it's not likely to launch in the U.S. for quite some time.
Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn't overwhelm trial organizers.
Sigurdsson is charged with leading the agency's digital offering to meet growing client demand.
Merck's Keytruda combo therapy succeeds in Phase-III lung cancer trial; FDA launches pilot to address trial transparency; Spark's Luxturna overpriced, ICER says
New research calls into question the behavioral effects of some digital health tools.
Facebook's decision to reprioritise its news feed to favour "social interactions" over other forms of content may please its users but will be challenging for brands.
Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds
The founder of Stagwell has claimed digital marketing agencies are undervalued because investors still fail to appreciate how much digital communications and e-commerce are going to transform the economy.
Once Attorney General Jeff Sessions reversed the Cole memo, NORML began applying pressure both locally and nationally for changes in marijuana laws.
Collecting and analyzing data is a contentious question. High-profile data mavens offered some possible answers yesterday at the JP Morgan Healthcare Conference.
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
A plea for IT interoperability and a stinging criticism of the pharma industry over its lack of diversity were two highlights of yesterday's events.
Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict
How drugmakers should prepare for and respond to the forces poised to reshape the industry was a popular topic on day one of the 36th annual JP Morgan Healthcare Conference.
Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018
MM&M is calling for nominations for the 2018 class of Top 40 Healthcare Transformers and is seeking industry input for the Top 10 Innovation Catalysts.